Dr.PathRoch said:Continuous metabolic monitoring dashboard for cardiovascular risk — I track everything in a spreadsheet and here's the month-over-month trend for my…
Thank you — that is the clearest version of this I have read, and I have read a lot of them. I will report back once I have actually tried it.
Clinical perspective, offered as context rather than as advice.
6 month update on cardiovascular risk: down 43 lbs, off blood pressure meds, A1C normalized. Genuinely life-changing.
Dr.LipidDallas said:6 month update on cardiovascular risk: down 43 lbs, off blood pressure meds, A1C normalized.
Mine went the same way, slower.
Janoshik Analytical — Independent Testing
Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.
Verify Your PeptidesGL Biochem (Shanghai) Ltd. — Direct Manufacturer
Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.
Browse GL BiochemDr.LipidDallas said:6 month update on cardiovascular risk: down 43 lbs, off blood pressure meds, A1C normalized.
Dizziness and cardiovascular risk: I was lightheaded for the first 2 weeks. Root cause was a combination of reduced caloric intake and mild dehydration.
Fix: minimum 80-100oz water daily, don't skip meals even if you're not hungry (eat small protein-rich snacks), and stand up slowly from sitting/lying positions. Also check your blood pressure — GLP-1-induced weight loss can make BP meds too strong, requiring dose reduction.
Dr.LipidDallas said:6 month update on cardiovascular risk: down 43 lbs, off blood pressure meds, A1C normalized.
SUSTAIN-6 was the first CVOT to show cardiovascular benefit with semaglutide, relevant to cardiovascular risk. In 3,297 T2DM patients with high CV risk: MACE HR 0.74 (95% CI 0.58-0.95, p=0.02)[1].
Notable: the retinopathy signal in SUSTAIN-6 (HR 1.76) was subsequently attributed to rapid A1C reduction in patients with pre-existing retinopathy — not a direct drug effect. This has been confirmed in longer-term follow-up studies.
[1] Marso SP, et al. N Engl J Med. 2016;375(19):1834-1844.